IRD

Unitaid Awards Medincell up to $6 million Extension Grant to Fight Malaria

Retrieved on: 
Monday, April 8, 2024
Health, Infectious Diseases, Research, Pharmaceutical, Science, Biotechnology, WHO, Ivermectin, Unitaid, IRD, Death, Malaria, IRSS, Vaccine

Global health agency Unitaid has awarded Medincell (Paris:MEDCL) an extension grant of up to US$ 6 million over three years to fund the clinical phase 1 activities of long-acting injectable mdc-STM.

Key Points: 
  • Global health agency Unitaid has awarded Medincell (Paris:MEDCL) an extension grant of up to US$ 6 million over three years to fund the clinical phase 1 activities of long-acting injectable mdc-STM.
  • If proven safe, effective, and acceptable, mdc-STM could have a significant impact on transmission of malaria among vulnerable populations in high-transmission areas.
  • mdc-STM is an investigational three-month active injectable formulation of ivermectin using Medincell’s BEPO® technology to fight malaria transmission.
  • Medincell is committed to the fight against the major global health threats, such as malaria that remains endemic in 85 countries representing 50% of the world's population.

BlueRock Therapeutics and Foundation Fighting Blindness announce collaboration to expand the Uni-Rare natural history study of patients living with inherited retinal diseases

Retrieved on: 
Monday, March 25, 2024
Retina, Research, Gene, Development, IRD, Leber congenital amaurosis, Retinitis pigmentosa, Paratriathlon, Patient, Bayer, Foundation Fighting Blindness, Visual impairment, University, Wilfrid Sellars, Senior, IND, Therapy, IPSC, Usher syndrome, B cell, Pharmaceutical industry

The new cohort will include patients living with IRDs caused by mutations in multiple genes.

Key Points: 
  • The new cohort will include patients living with IRDs caused by mutations in multiple genes.
  • “BlueRock is developing a pipeline of cell therapies that we believe has great potential for restoring vision in people living with blindness caused by retinal disease,” said Ahmed Enayetallah, Senior Vice President and Head of Development for BlueRock Therapeutics.
  • Primary photoreceptor diseases are a subgroup of inherited retinal diseases that includes retinitis pigmentosa and cone- rod dystrophies.
  • OpCT-001 aims to restore vision loss caused by these diseases by replacing degenerated tissue in the retina with functional cells.

Quarterhill Awarded $5.3 Million Tennessee Statewide Weigh-In-Motion Contract

Retrieved on: 
Thursday, March 7, 2024
TDOT, TSX, Interstate Highway System, Tennessee Highway Patrol, WIM, Safety, IRD, State, Intelligent transportation system

SASKATOON, SK, March 7, 2024 /PRNewswire/ - Quarterhill Inc. ("Quarterhill" or the "Company") (TSX: QTRH) (OTCQX: QTRHF), a leading provider of tolling and enforcement solutions in the Intelligent Transportation System ("ITS") industry, announces that its wholly-owned subsidiary, International Road Dynamics Inc. ("IRD"), has been awarded a $5.3 million contract by the Tennessee Department of Transportation ("TDOT") to install Weigh-In-Motion ("WIM") systems at 28 sites on interstate and state routes across Tennessee.

Key Points: 
  • SASKATOON, SK, March 7, 2024 /PRNewswire/ - Quarterhill Inc. ("Quarterhill" or the "Company") (TSX: QTRH) (OTCQX: QTRHF), a leading provider of tolling and enforcement solutions in the Intelligent Transportation System ("ITS") industry, announces that its wholly-owned subsidiary, International Road Dynamics Inc. ("IRD"), has been awarded a $5.3 million contract by the Tennessee Department of Transportation ("TDOT") to install Weigh-In-Motion ("WIM") systems at 28 sites on interstate and state routes across Tennessee.
  • TDOT is promoting the advancement of WIM in the state through the development of a statewide WIM program.
  • "We are pleased to collaborate with TDOT on this project to elevate highway safety and efficiency in Tennessee," said Chuck Myers, CEO of Quarterhill.
  • This project is our first major initiative in Tennessee, and we look forward to exploring opportunities to expand our footprint further in the State."

Foundation Fighting Blindness Hosting Webinar for Eye Care Professionals: Best Clinical Practices for Patients with Inherited Retinal Diseases

Retrieved on: 
Tuesday, February 13, 2024
Therapy, Retinitis pigmentosa, Leber congenital amaurosis, Caregiver, Doctor of Philosophy, Ear, SCCO, University of Iowa, MD, Optometry, Brain damage, Genetic testing, University, Foundation Fighting Blindness, Visual impairment, Stargardt disease, Genetics, OD, Patient, IRD, Rehabilitation, Harvard Medical School, Marshall B. Ketchum University, Science, Usher syndrome, Research, Acquired brain injury, Nursing

COLUMBIA, Md., Feb. 13, 2024 /PRNewswire/ -- The Foundation Fighting Blindness, the driving force in the global development of treatments and cures for blinding diseases, will host a webinar for eye care professionals on the best practices for managing their patients with inherited retinal diseases (IRDs), including retinitis pigmentosa, Usher syndrome, Stargardt disease, and Leber congenital amaurosis. This webinar will be a part of the March Envisioning a Path to Hope initiative, raising awareness among eye care professionals for the valuable resources the Foundation provides IRD patients and caregivers.

Key Points: 
  • This webinar will be a part of the March Envisioning a Path to Hope initiative, raising awareness among eye care professionals for the valuable resources the Foundation provides IRD patients and caregivers.
  • "With nearly 50 clinical trials underway for emerging IRD therapies and no-cost genetic testing available for patients, eye care professionals can do so much to help IRD patients on their challenging journeys," says Michelle Glaze, director of professional outreach, Foundation Fighting Blindness.
  • "We are delighted to host this informative webinar to empower eye doctors to communicate hope and a path forward for their IRD patients and families."
  • She treats patients in the clinical departments of Acquired Brain Injury and Low Vision Rehabilitation, where she also conducts genetic testing for inherited eye conditions.

Sysmex and Hitachi High-Tech Agree to Collaborate on Development of New Genetic Testing Systems

Retrieved on: 
Thursday, February 8, 2024
Quality of life, FS, DNA, Running, Diagnosis, Genetic testing, Hitachi, Blood, Sysmex Corporation, IRD, NGS, CE, Insurance, Cancer, Digital technology, Quality, Vaccine

TOKYO, Feb 8, 2024 - (JCN Newswire) - Sysmex Corporation and Hitachi High-Tech Corporation announce that both companies have agreed to collaborate in the development of genetic testing systems based on capillary electrophoresis sequencers (CE sequencers)(1).

Key Points: 
  • TOKYO, Feb 8, 2024 - (JCN Newswire) - Sysmex Corporation and Hitachi High-Tech Corporation announce that both companies have agreed to collaborate in the development of genetic testing systems based on capillary electrophoresis sequencers (CE sequencers)(1).
  • To achieve widespread clinical realization, Sysmex and Hitachi High-Tech will develop more efficient genetic testing systems at a lower cost, aiming at expanding optimal genetic testing for individual diseases.
  • In recent years, there has been active development of assay reagents using next generation sequencer (NGS)(2) in the genetic testing field.
  • Having achieved the milestones in the FS agreement, Sysmex and Hitachi High-Tech have agreed, as the next step, to collaborate on the development of genetic testing systems with a view to their widespread adoption in the clinical setting.

FUJIFILM Cellular Dynamics and Opsis Therapeutics Announce License with BlueRock Therapeutics for iPSC-derived Cell Therapy Candidate

Retrieved on: 
Tuesday, January 23, 2024
Patient, B cell, Therapy, Cell, IPSC, IRD, Paratriathlon, Partnership, Retina, IND, Human, AMD, Bayer, Peripheral vision, Pharmaceutical industry

an exclusive, worldwide license to develop and commercialize an iPSC-derived cell therapy candidate for the treatment of human retinal diseases.

Key Points: 
  • an exclusive, worldwide license to develop and commercialize an iPSC-derived cell therapy candidate for the treatment of human retinal diseases.
  • BlueRock Therapeutics, a clinical stage cell therapy company and wholly owned independently operated subsidiary of Bayer AG, exercised its option to exclusively license OpCT-001, an iPSC-derived photoreceptor cell therapy for human retinal diseases.
  • Following the option exercise by BlueRock Therapeutics, FUJIFILM Cellular Dynamics and Opsis Therapeutics received an undisclosed license fee and are eligible to receive payments upon achievement of certain development and commercial milestones.
  • OpCT-001 is the first iPSC therapy candidate to be licensed from the strategic research and development alliance that FUJIFILM Cellular Dynamics, Opsis Therapeutics, and BlueRock Therapeutics entered in 2021 to discover and develop off-the-shelf iPSC-derived cell therapies for ocular diseases.

UTulsa's Hurricane Ventures announces investments in BPEndo, Titan Intake

Retrieved on: 
Monday, December 11, 2023
Titan, Entrepreneurship, Venture capital, Food, University of Tulsa, IRD, Investment, Patient, Multimedia, Faculty, Collins College, FDA, Artificial intelligence, Friends, University, Partnership, Growth, Innovation, Physician, Business, Colonoscopy, Philosophy, Cryptocurrency

TULSA, Okla., Dec. 11, 2023 /PRNewswire/ -- The University of Tulsa and Hurricane Ventures have announced two new start-up investments, BPEndo and Titan Intake.

Key Points: 
  • TULSA, Okla., Dec. 11, 2023 /PRNewswire/ -- The University of Tulsa and Hurricane Ventures have announced two new start-up investments, BPEndo and Titan Intake.
  • Hurricane Ventures aims to commercialize intellectual property, create new ventures and attain venture capital funding.
  • "We are excited by the continued momentum of Hurricane Ventures," said Chris Wright, director of UTulsa's Center for Innovation & Entrepreneurship.
  • Created in partnership with 46 Venture Capital, Hurricane Ventures is a funding catalyst for student, alumni, faculty and staff startups.

International Road Dynamics Awarded $4.1 Million North Carolina Weigh Station Maintenance Contract

Retrieved on: 
Monday, November 6, 2023
DOT, WIM, North Carolina Department of Transportation, IRD, Maintenance, North Carolina State Highway Patrol, The Company, Safety, NCDOT, TSX, Mobile phone, Transport

IRD will maintain and service commercial motor vehicle enforcement technology at 18 locations throughout North Carolina.

Key Points: 
  • IRD will maintain and service commercial motor vehicle enforcement technology at 18 locations throughout North Carolina.
  • SASKATOON, SK, Nov. 6, 2023 /PRNewswire/ - International Road Dynamics Inc. ("IRD"), a wholly-owned subsidiary of Quarterhill Inc. ("Quarterhill" or the "Company") (TSX: QTRH) (OTCQX: QTRHF), announced today that it has been awarded a three year $4.1 million contract by North Carolina Department of Transportation ("NCDOT") to maintain, service, repair and calibrate the commercial vehicle enforcement technology located at 18 permanent and virtual truck weigh stations throughout the state.
  • This new contract consolidates and expands the maintenance activities for all active systems in North Carolina into a single statewide maintenance agreement.
  • Most importantly, safety for all drivers is enhanced by removing unsafe trucks and oversized vehicles from the state's roadways."

International Road Dynamics Awarded $2.8 Million Contract for Caltrans Ramp E-Screening System

Retrieved on: 
Wednesday, October 25, 2023
ITS, Vehicle, WIM, TACS, IRD, Congestion, Cajón, The Company, Overweight, California Department, TSX, USDOT, Road, California Department of Transportation

SASKATOON, SK, Oct. 25, 2023 /PRNewswire/ - International Road Dynamics Inc. ("IRD"), a wholly-owned subsidiary of Quarterhill Inc. ("Quarterhill" or the "Company") (TSX: QTRH) (OTCQX: QTRHF), announced today that it has been awarded a $2.8 million contract by the California Department of Transportation ("Caltrans").

Key Points: 
  • SASKATOON, SK, Oct. 25, 2023 /PRNewswire/ - International Road Dynamics Inc. ("IRD"), a wholly-owned subsidiary of Quarterhill Inc. ("Quarterhill" or the "Company") (TSX: QTRH) (OTCQX: QTRHF), announced today that it has been awarded a $2.8 million contract by the California Department of Transportation ("Caltrans").
  • The contract covers the supply of a high-speed Weigh-In-Motion ("WIM") pre-clearance system and a sophisticated Ramp E-screening system at the Cajon weigh station.
  • The E-screening system will target overweight and unsafe vehicles with the aim of enhancing enforcement efficiency and highway safety.
  • "We are honored to partner with Caltrans in their pursuit of highway safety and efficiency," said Rish Malhotra, IRD's CEO.

Ocugen Announces Positive Clinical Study Update from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA)

Retrieved on: 
Wednesday, September 13, 2023
Vaccine, Retina, IRD, Schepens Eye Research Institute, CEP290, LCA, Cohort, Biotechnology, Eye, Clinical trial, Duke University School of Medicine, Quality of life, Hope, Mutation, Research, Paratriathlon, DSM-IV codes, Retinitis pigmentosa, RP, Associate, Trial of the century, Șaeș, NR2E3, Development, Patient, Webcast, Married to Medicine: Los Angeles, Ageing, RHO, Principal, Leber congenital amaurosis, Safety, Pharmaceutical industry, Medical device, Television, Rhodopsin, Medicine, Ophthalmology

This clinical study update is an extension of results provided by Ocugen on April 14, 2023, and includes additional subjects from the high dose group.

Key Points: 
  • This clinical study update is an extension of results provided by Ocugen on April 14, 2023, and includes additional subjects from the high dose group.
  • Ocugen further expanded this Phase1/2 trial to enroll LCA patients with CEP290 gene mutation and pediatric patients with NR2E3, RHO and CEP290 mutations.
  • Our team's unwavering dedication to advancing modifier gene therapy research demonstrated positive preliminary clinical results that offer renewed hope to patients and their families.
  • “In my view, the clinical study update supports the gene-agnostic mechanism of action of OCU400 in RHO patients.